Flaxseed Lignan (Brevail)
Flaxseed Lignan (Brevail)
PCOS is a disorder which is characterized by hyperandrogenism (high serum male hormone
 levels), ovulatory dysfunction, and polycystic ovaries (multiple follicles-over 12- in the
 ovary). There is no universally accepted definition for PCOS. The Rotterdam criteria require
 2 of 3 criteria for diagnosis, including hyperandrogenism (clinical hirsutism or serum
 hormone measurement), oligomenorrhea/amenorrhea, and ultrasound findings of polycystic
 ovaries.

 This study is a prospective randomized pilot study designed to evaluate the effects of
 flaxseed supplementation (with Brevail) on hormonal and lipid metabolism balance in
 polycystic ovarian syndrome (PCOS) patients.
Inclusion Criteria:

 -  Must be 18 to 40 year old female with:

 -  Diagnosis of PCOS by menstrual irregularity (fewer than 9 menses annually/interval
 over 40 days), Ferriman-Galleway score >8, and/or hyperandrogenemia defined as total
 testosterone >80ng/dl or bioavailable testosterone >8.4 ng/dl.

 -  Mentally competent.

 Exclusion Criteria:

 -  Use of oral contraceptives, spironolactone, or insulin-sensitizing agents within the
 past 2 months.

 -  Long-term or chronic use of oral antibiotics.

 -  Hysterectomy.

 -  FSH >15.

 -  Pregnancy/lactation.

 -  Consumption of flaxseed within the last month.

 -  Diagnosis of thyroid disease, nonclassical adrenal hyperplasia, and
 hyperprolactinemia.

 -  Use of any dietary fiber supplements which are newly started (within the past 6
 months) and agreement not to use any new fiber supplements during the study period.